AUTHORS
Serhan Unlu, MD, Karol K Gostomczyk2, Vibha Balasubramaniam3, Maxwell Hou, N/A4, Zachary Brady, BS5, Atsushi Marumo, MD6, Ana Plesca, MD7, Arda Durmaz, PhD8, Charlotte Zurowski9, Jackson Hensley, N/A10, Luca Guarnera, MD11, Aashray Mandala, BS12, Mark David Orland, MD, PhD13, Nandini Rajaram Siva, MD14, Varun K. Venkatesh, N/A15, Ajitesh Reddy Busireddy, N/A16, Kartik Lakhotiya, MS17, Carmelo Gurnari, MD,PhD18, Carlos Bravo-Perez, MD19, Chantana Polprasert, MD20, Jaroslaw P. Maciejewski, MD, PhD, FACP21, Valeria Visconte, PhD22
AFFILIATIONS
1 Cleveland Clinic, Cleveland, Ohio, United States
2 Cleveland Clinic, Cleveland, Ohio, United States
3 Cleveland Clinic, Cleveland, Ohio, United States
4 Cleveland Clinic, Cleveland, Ohio, United States
5 Cleveland Clinic, Cleveland, Ohio, United States
6 Cleveland Clinic, Cleveland, Ohio, United States
7 Cleveland Clinic, Cleveland, Ohio, United States
8 Cleveland Clinic, Cleveland, Ohio, United States
9 Cleveland Clinic, Cleveland, Ohio, United States
10 Cleveland Clinic, Cleveland, Ohio, United States
11 Cleveland Clinic, Cleveland, Ohio, United States, University of Rome Tor Vergata, Rome, Italy
12 Cleveland Clinic, Cleveland, Ohio, United States
13 Cleveland Clinic, Cleveland, Ohio, United States
14 Cleveland Clinic, Cleveland, Ohio, United States
15 Cleveland Clinic, Cleveland, Ohio, United States
16 Cleveland Clinic, Cleveland, Ohio, United States
17 Cleveland Clinic, Cleveland, Ohio, United States
18 Cleveland Clinic, Cleveland, Ohio, United States, University of Rome Tor Vergata, Rome, Italy
19 Cleveland Clinic, Cleveland, Ohio, United States, Hospital Universitario Morales Meseguer, Murcia, Spain
20 Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand
21 Cleveland Clinic, Cleveland, Ohio, United States
22 Cleveland Clinic, Cleveland, Ohio, United States
ABSTRACT
Introduction. Inborn errors of immunity (IEI) identify a very diverse family of diseases with hallmark features of excessive or defective immune response. We reported that IEI intersect bone marrow failure syndromes (BMFS) and propensity for clonal and oligoclonal T cell expansions implicated in immune pathogenesis of these conditions. [Blood (2023) 142:707; PMID: 40309770]
Among over 400 genes associated with IEI by the 2022 IUIS IEI Classification of IEI, [PMID:36198931] the Hepatitis A Virus Cellular Receptor 2 (HAVCR2/TIM3) alterations are linked to autoimmunity. Located on 5q33.3, HAVCR2 encodes TIM-3, a transmembrane protein expressed on interferon-γ producing CD4+ Th1 and CD8+ Tc1 and NK cells and acts as a negative immune checkpoint inhibitor. Promoter and 5’ UTR of HAVCR2 contain putative binding sites for T-bet, GATA-1/3, RARa, p300 among others. CD8+T cells with high expression of TIM-3 have been linked to increased cancer risk, particularly of digestive system and lymphoma. [PMID:32133384]
To date, the occurrence of homozygous or compound heterozygous loss of function HAVCR2 variants (p.Y82C; p.I97M; p.T101I) were implicated in subcutaneous panniculitis-like T-cell lymphoma (SPTCL) and associated with severe hemophagocytic lymphohistiocytosis syndrome. p.I97M occurs in European/Caucasian ancestry while p.Y82C and pT101I are linked primarily to East Asian and Polynesian populations.
Aim. Having noted alterations of HAVCR2 among a spectrum of BMFS, we investigated the clinical association of germline variants to specific disease phenotypes.
Results. WES/WGS were performed on BM or peripheral blood of 400 BMFS cases (AA, AA/PNH, PNH, PRCA, LGL). Sanger sequencing with primers spanning HAVCR2 exon 2 was conducted for validation of mutant cases carrying hotspot mutations and to sequence additional cases (n=110). RNA-sequencing was conducted in a subcohort of AA/PNH. We identified 10 patients (PNH, 3; AA/PNH, 2; pancytopenia and marrow fibrosis of unknown etiology, 1; SDS, 1; PRCA/PRCA-MGUS, 2; MDS, 1). Median age of diagnosis was 32 (range, 16-64 years). Patients presented with anemia (n=5/10; median Hgb 11.35g/dL), leukopenia (n=6/10; median WBC 3.5k/uL), thrombocytopenia (n=6/10, median PLT count 134k/uL). In total, 5/9 patients had a PNH clone at diagnosis (58% median granulocyte clone) and interestingly, in 3 patients clone size decreased over time, with one case who initially had a 94% PNH clone almost losing the clone to only 0.38% 14 years after diagnosis.
At diagnosis, 1/8 patients had a karyotypic abnormality [del(5q)] with two additional patients acquiring karyotypic abnormalities in follow up. An AA/PNH patient carrying a variant of this gene developed MDS and acquired del(7) 5 years after being diagnosed. A clone with a stopgain PIGA mutation (p.L23X, 10%) coexisted at progression with STAG2 (p.R305X, 18%) and TET2 mutations. The SDS patient developed del(20q) with double TP53 hits (p.R248W, 9.5%; p.V216M, 4.1%) and a VUS in PRPF8 (p.M1370V, 10.2%). The MDS patient with del(5q) progressed to AML with canonical DNMT3A (p.R882C, 23%) and two frameshift insertions in RUNX1 (p.A53fs,13%) and JARID2 (p.Q691fs, 23%) and died 2 years after diagnosis. The rest of the cases did not have any common myeloid-related gene mutations.
Three patients were found to carry canonical HAVCR2 variants in the IgV-like domain described in SPTCL.[PMID:30792187] Two patients with PRCA carried p.T101I and p.I97M while one PNH patient carried p.Y82C. The remainder of patients harbored novel non canonical variants in the cytoplasmic domain (224-301) estimated to be deleterious (SIFT, normalized score <0.05) (p.P.277L [gnomAD: 0.00777374] in 5 cases; p.R259H [gnomAD: 0.008077] in 2 cases). Since upstream SNPs have been found to hit binding sites and have been associated with cancer risk and lymphoma, we reviewed WES data for any novel change finding alterations in non-coding regions (3’UTR; c.*63C>G) in one patient and splice polypyrimidine tract variants in 6 additional cases [c.677-16G>C (n=2), c.479-12_479-9del (n=2), c.479-10_479-9dup (n=2)].
Expression analysis showed unaltered levels of mRNA for this gene in AA/PNH cases compared to healthy controls with wild type HAVCR2 (median expression, 2.558 vs 2.684; number, 36 vs 64).
Conclusions. These findings support our previous discovery of occurrence of the IEI spectrum in BMFS and warrant further screening in an expanded cohort of BMFS.
DISCLOSURES
Serhan Unlu, MD: No relevant conflicts of interest to declare.